0
research-article

Improved Method for the ASTM Platelet and Leukocyte Assay: Use of Minimal Heparinization in a Screening Test for Hemocompatibility of Blood-Contacting Medical Devices

[+] Author and Article Information
Timothy Schatz

American Preclinical Services, 8945 Evergreen Blvd., Coon Rapids, MN 55433
tschatz@apsemail.com

Sarah Howard

American Preclinical Services, 8945 Evergreen Blvd., Coon Rapids, MN 55433
showard@apsemail.com

Deanna Porter

Abbott Laboratories, 177 East County Road B, St. Paul, MN 55117
DPorter@sjm.com

Kent J Grove

Abbott Laboratories, 177 East County Road B, St. Paul, MN 55117
KGrove@sjm.com

Mark E Smith

American Preclinical Services, 8945 Evergreen Blvd., Coon Rapids, MN 55433
msmith@apsemail.com

Yan Chen

American Preclinical Services, 8945 Evergreen Blvd., Coon Rapids, MN 55433
ychen@apsemail.com

1Corresponding author.

ASME doi:10.1115/1.4041805 History: Received April 16, 2018; Revised August 03, 2018

Abstract

Most blood-contacting medical devices must be assessed for potential thrombogenicity prior to regulatory approval. A common assay for screening and qualifying devices involves monitoring the reduction of platelet and leukocyte counts in whole blood exposed to the device. We have validated an improved method for assessing a device's effect on platelet activation and surface adhesion, offering significant improvement over the current ASTM F2888-13 method which uses blood fully anticoagulated by acidified citrate (known to significantly inhibit platelet responsiveness). Our method uses minimal heparinization (final concentration 1 IU/ml) to optimize the response to commonly used control materials, latex, black rubber, and high-density polyethylene (HPDE). We also have shown the assay's capacity to appropriately assess a legally marketed comparator device (LMCD) with a documented clinical history. The test materials were prepared for incubation and allowed to remain in contact with the citrated or heparinized blood for ~1 hour at 37° C. A complete blood count (CBC) was performed prior to exposure and at the end of the incubation period and reductions in platelet and leukocyte counts were recorded. Results from citrate-anticoagulated assay showed only a marginal response to the positive control, black rubber. Using heparinized blood, the assay generated a robust response to the positive controls, the "intermediate scoring" controls, and also assessed a legally marketed and approved device as clearly non-thrombogenic. This modification adds robustness and sensitivity to this quick and inexpensive thrombogenicity assay and should be incorporated into the next ASTM standards

Copyright (c) 2018 by ASME
Your Session has timed out. Please sign back in to continue.

References

Figures

Tables

Errata

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related Journal Articles
Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In